Carfilzomib is an anti-cancer tetrapeptide epoxyketone drug and is used for the treatment of multiple myeloma.
|Mechanism of Action||Carfilzomib prevents tumor growth by inhibiting 20S proteasome activity which leads to an accumulation of polyubiquinated proteins, and ultimately, cell cycle arrest or apoptosis.|
|References||Pautasso, Chiara, Sara Bringhen, Chiara Cerrato, Valeria Magarotto, and Antonio Palumbo. "The Mechanism of Action, Pharmacokinetics, and Clinical Efficacy of Carfilzomib for the Treatment of Multiple Myeloma." Expert Opinion on Drug Metabolism & Toxicology 9.10 (2013): 1371-379.|
Kortuem, K. M., and A. K. Stewart. "Carfilzomib." Blood 121.6 (2013): 893-97.